AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:10:00Z
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | 375090.00M | 302571.00M | 366235.00M | -60754.00000M | 94896.00M |
| Minority interest | -21.00000M | -107.00000M | 4140.00M | 4003.00M | 4006.00M |
| Net income | 317017.00M | 230059.00M | 376005.00M | 44241.00M | 109126.00M |
| Selling general administrative | 997309.00M | 886361.00M | 875663.00M | 964737.00M | 717599.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2783406.00M | 2462160.00M | 2203504.00M | 2201424.00M | 1437534.00M |
| Reconciled depreciation | 664400.00M | 583151.00M | 559671.00M | 583649.00M | 272446.00M |
| Ebit | 490505.00M | 460844.00M | 509269.00M | 100408.00M | 103937.00M |
| Ebitda | 1209188.00M | 1052329.00M | 1174537.00M | 687901.00M | 376383.00M |
| Depreciation and amortization | 718683.00M | 591485.00M | 665268.00M | 587493.00M | 272446.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 490505.00M | 460844.00M | 509269.00M | 100408.00M | 204969.00M |
| Other operating expenses | 3536972.00M | 3108161.00M | 2688543.00M | 3190780.00M | 1936859.00M |
| Interest expense | 169698.00M | 166607.00M | 248631.00M | 165006.00M | 48158.00M |
| Tax provision | 58052.00M | 72405.00M | -9936.00000M | -105044.00000M | -14118.00000M |
| Interest income | 62913.00M | 23700.00M | 105521.00M | 11202.00M | 6619.00M |
| Net interest income | -106785.00000M | -142907.00000M | -143110.00000M | -146649.00000M | -60959.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 58052.00M | 72405.00M | -9936.00000M | -105044.00000M | -14118.00000M |
| Total revenue | 4027478.00M | 3569006.00M | 3197812.00M | 3291188.00M | 2097224.00M |
| Total operating expenses | 2292900.00M | 2001315.00M | 1694235.00M | 2101016.00M | 1277169.00M |
| Cost of revenue | 1244072.00M | 1106846.00M | 994308.00M | 1089764.00M | 659690.00M |
| Total other income expense net | -115415.00000M | -158273.00000M | -143034.00000M | -161162.00000M | -4510.00000M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 317038.00M | 230166.00M | 376171.00M | 44290.00M | 109014.00M |
| Net income applicable to common shares | 317017.00M | 230059.00M | 376005.00M | 44241.00M | 135192.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 13957750.00M | 13178018.00M | 12912293.00M | 12821094.00M | 13872322.00M |
| Intangible assets | 4269657.00M | 3818544.00M | 3909106.00M | 4171361.00M | 4860368.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 160867.00M | 141098.00M | 122789.00M | 114196.00M | 109666.00M |
| Total liab | 7603079.00M | 7494495.00M | 7735116.00M | 8093608.00M | 8708734.00M |
| Total stockholder equity | 6354122.00M | 5683019.00M | 5173037.00M | 4723483.00M | 5159582.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 1493107.00M | 1425440.00M | 790704.00M | 682282.00M | 1194152.00M |
| Common stock | 1676345.00M | 1676263.00M | 1668145.00M | 1668123.00M | 1643585.00M |
| Capital stock | 1676345.00M | 1676263.00M | 1668145.00M | 1668123.00M | 1643585.00M |
| Retained earnings | 1541146.00M | 1479716.00M | 1509906.00M | 1369972.00M | 1569365.00M |
| Other liab | 544129.00M | 1207347.00M | 831045.00M | 1082848.00M | 1110462.00M |
| Good will | 4790723.00M | 4407749.00M | 4033917.00M | 4012528.00M | 4161403.00M |
| Other assets | 429328.00M | 678704.00M | 454110.00M | 10351662.00M | 176463.00M |
| Cash | 533530.00M | 849695.00M | 966222.00M | 637614.00M | 702093.00M |
| Cash and equivalents | 533530.00M | 389058.00M | 335027.00M | 188640.00M | 462890.00M |
| Total current liabilities | 2481940.00M | 2145730.00M | 1773176.00M | 2175898.00M | 2510931.00M |
| Current deferred revenue | - | - | 616481.00M | 587983.00M | 119485.00M |
| Net debt | 3848811.00M | 3495716.00M | 3669149.00M | 4455690.00M | 5048858.00M |
| Short term debt | 339600.00M | 203993.00M | 22153.00M | 586817.00M | 984946.00M |
| Short long term debt | 339600.00M | 203993.00M | 22153.00M | 586817.00M | 984946.00M |
| Short long term debt total | 4382341.00M | 4345411.00M | 4635371.00M | 5093304.00M | 5750951.00M |
| Other stockholder equity | 3136631.00M | 2527040.00M | 1994986.00M | 1685388.00M | 1946632.00M |
| Property plant equipment | 1691229.00M | 1582800.00M | 1453917.00M | 1386370.00M | 1331931.00M |
| Total current assets | 2397956.00M | 2593642.00M | 2712893.00M | 2469432.00M | 3050658.00M |
| Long term investments | 378857.00M | 330133.00M | 348350.00M | 369455.00M | 306899.00M |
| Net tangible assets | - | -2543274.00000M | -2769986.00000M | -3460406.00000M | -3809435.00000M |
| Short term investments | 20174.00M | 25305.00M | 36598.00M | 15822.00M | 23276.00M |
| Net receivables | 681693.00M | 724377.00M | 812714.00M | 784921.00M | 749119.00M |
| Long term debt | 4042741.00M | 4141418.00M | 4613218.00M | 4506487.00M | 4766005.00M |
| Inventory | 986457.00M | 853167.00M | 753881.00M | 759599.00M | 986744.00M |
| Accounts payable | 649233.00M | 516297.00M | 343838.00M | 318816.00M | 212348.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | 92564.00M | -638421.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | 1668145.00M | 1668123.00M | 1643585.00M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | -59552.00000M | -87463.00000M | -57142.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 63325.00M | 82611.00M | 100341.00M | 103846.00M | 87472.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 11559794.00M | 10584376.00M | 10199400.00M | 10351662.00M | 10821664.00M |
| Capital lease obligations | - | - | - | - | 0.00000M |
| Long term debt total | 4042741.00M | 4141418.00M | 4613218.00M | 4506487.00M | 4766005.00M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -607102.00000M | -198125.00000M | 62008.00M | 292119.00M | -2835698.00000M |
| Change to liabilities | 0.00000M | 125157.00M | 36620.00M | -29932.00000M | -16413.00000M |
| Total cashflows from investing activities | -607102.00000M | -198125.00000M | 393530.00M | 292119.00M | -2835698.00000M |
| Net borrowings | -285071.00000M | -600477.00000M | -660504.00000M | -586090.00000M | 3161504.00M |
| Total cash from financing activities | -709148.00000M | -1070265.00000M | -1088354.00000M | -1005213.00000M | 2946237.00M |
| Change to operating activities | 63568.00M | -66289.00000M | 222499.00M | 44458.00M | -26284.00000M |
| Net income | 317038.00M | 230166.00M | 376171.00M | 44290.00M | 109014.00M |
| Change in cash | -316165.00000M | -116527.00000M | 328608.00M | -65108.00000M | 407120.00M |
| Begin period cash flow | 849695.00M | 966222.00M | 637614.00M | 702722.00M | 294973.00M |
| End period cash flow | 533530.00M | 849695.00M | 966222.00M | 637614.00M | 702093.00M |
| Total cash from operating activities | 977156.00M | 1123105.00M | 1010931.00M | 669752.00M | 328479.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 664400.00M | 583151.00M | 559671.00M | 583649.00M | 272446.00M |
| Other cashflows from investing activities | 26587.00M | -1007.00000M | -8851.00000M | -1256.00000M | 73318.00M |
| Dividends paid | -279416.00000M | -283665.00000M | -283357.00000M | -282582.00000M | 142952.00M |
| Change to inventory | -79155.00000M | -46148.00000M | 25978.00M | 137492.00M | 58678.00M |
| Change to account receivables | - | 127294.00M | -9316.00000M | -34826.00000M | -13382.00000M |
| Sale purchase of stock | -26929.00000M | -77531.00000M | -2141.00000M | -3737.00000M | -1172.00000M |
| Other cashflows from financing activities | -2732.00000M | 140742.00M | -35002.00000M | -5593.00000M | -36229.00000M |
| Change to netincome | 21003.00M | 169881.00M | -200526.00000M | -75330.00000M | -49042.00000M |
| Capital expenditures | 633689.00M | 186037.00M | 236468.00M | 217710.00M | 134114.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -25264.00000M | 98605.00M | 275781.00M | 94672.00M | 75946.00M |
| Stock based compensation | 60672.00M | 43374.00M | 37663.00M | 29122.00M | 20084.00M |
| Other non cash items | -97742.00000M | 95404.00M | -228419.00000M | 23063.00M | -134893.00000M |
| Free cash flow | 343467.00M | 937068.00M | 774463.00M | 452042.00M | 194365.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.16 1.21% | 13.07 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
| ZTS Zoetis Inc |
2.48 1.64% | 153.36 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.37 1.14% | 32.07 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
6.97 4.40% | 165.33 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
-0.73 2.83% | 25.04 | 32.60 | 11.59 | 0.01 | 0.88 | 0.02 | 0.07 |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668
| Name | Title | Year Born |
|---|---|---|
| Mr. Christophe Weber | Pres, CEO & Representative Director | 1966 |
| Mr. Constantine Saroukos | CFO & Representative Director | 1971 |
| Dr. Andrew S. Plump | Pres of R&D and Representative Director | 1965 |
| Dr. Seigo Izumo | Chair of Management Board | NA |
| Mr. Haruhiko Hirate | Member of Management Board | 1957 |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy | NA |
| Norimasa Takeda | Chief Accounting Officer & Corp. Controller | NA |
| Mr. Iwaaki Taniguchi | Sr. VP of Corp. Fin. & Controlling Department | NA |
| Mr. Gabriele Ricci | Chief Data & Technology Officer | 1978 |
| Mr. Christopher David O'Reilly | Global Head of Investor Relations & Global Fin. | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...